Localization of Damage in Progressive Hydroxychloroquine Retinopathy On and Off the Drug: Inner Versus Outer Retina, Parafovea Versus Peripheral Fovea
To evaluate the relative involvement of inner and outer retina in hydroxychloroquine (HCQ) retinopathy while on the drug, and after drug cessation, using data from spectral-domain optical coherence tomography (SD-OCT). A total of 102 SD-OCT scans were obtained from 11 patients (classified as having...
Saved in:
Published in | Investigative ophthalmology & visual science Vol. 56; no. 5; pp. 3415 - 3426 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
The Association for Research in Vision and Ophthalmology
01.05.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | To evaluate the relative involvement of inner and outer retina in hydroxychloroquine (HCQ) retinopathy while on the drug, and after drug cessation, using data from spectral-domain optical coherence tomography (SD-OCT).
A total of 102 SD-OCT scans were obtained from 11 patients (classified as having early, moderate, or severe stages of toxicity) over a period of 4 years after cessation of HCQ. The inner and outer retina boundaries were identified automatically to measure thickness and characterize progression topographically.
The segmentation of retinal layers was verified in SD-OCT cross-sections for all eyes and scans included in this study (a total of 102 scans). Topographic analysis showed that inner retina was not involved in HCQ toxicity to any meaningful degree, either between stages of retinopathy or after the drug is stopped. The characteristic bull's eye pattern of outer macula thinning appears when comparing moderate retinopathy (before any RPE damage) to the early stage. Later damage, as toxicity evolved to a severe stage, was diffuse across most of the macula. If the drug was stopped at an early or moderate stage, progression was limited to the first year and occurred diffusely without parafoveal localization.
Hydroxychloroquine retinopathy primarily involves outer retina (photoreceptors). Outer retinal thinning while using HCQ initially involves the parafovea, but becomes diffuse across the macula as damage progresses or after drug cessation. When HCQ is stopped at an early or moderate stage (before RPE damage), progression seems to be limited to the first year. |
---|---|
AbstractList | To evaluate the relative involvement of inner and outer retina in hydroxychloroquine (HCQ) retinopathy while on the drug, and after drug cessation, using data from spectral-domain optical coherence tomography (SD-OCT).
A total of 102 SD-OCT scans were obtained from 11 patients (classified as having early, moderate, or severe stages of toxicity) over a period of 4 years after cessation of HCQ. The inner and outer retina boundaries were identified automatically to measure thickness and characterize progression topographically.
The segmentation of retinal layers was verified in SD-OCT cross-sections for all eyes and scans included in this study (a total of 102 scans). Topographic analysis showed that inner retina was not involved in HCQ toxicity to any meaningful degree, either between stages of retinopathy or after the drug is stopped. The characteristic bull's eye pattern of outer macula thinning appears when comparing moderate retinopathy (before any RPE damage) to the early stage. Later damage, as toxicity evolved to a severe stage, was diffuse across most of the macula. If the drug was stopped at an early or moderate stage, progression was limited to the first year and occurred diffusely without parafoveal localization.
Hydroxychloroquine retinopathy primarily involves outer retina (photoreceptors). Outer retinal thinning while using HCQ initially involves the parafovea, but becomes diffuse across the macula as damage progresses or after drug cessation. When HCQ is stopped at an early or moderate stage (before RPE damage), progression seems to be limited to the first year. To evaluate the relative involvement of inner and outer retina in hydroxychloroquine (HCQ) retinopathy while on the drug, and after drug cessation, using data from spectral-domain optical coherence tomography (SD-OCT).PURPOSETo evaluate the relative involvement of inner and outer retina in hydroxychloroquine (HCQ) retinopathy while on the drug, and after drug cessation, using data from spectral-domain optical coherence tomography (SD-OCT).A total of 102 SD-OCT scans were obtained from 11 patients (classified as having early, moderate, or severe stages of toxicity) over a period of 4 years after cessation of HCQ. The inner and outer retina boundaries were identified automatically to measure thickness and characterize progression topographically.METHODSA total of 102 SD-OCT scans were obtained from 11 patients (classified as having early, moderate, or severe stages of toxicity) over a period of 4 years after cessation of HCQ. The inner and outer retina boundaries were identified automatically to measure thickness and characterize progression topographically.The segmentation of retinal layers was verified in SD-OCT cross-sections for all eyes and scans included in this study (a total of 102 scans). Topographic analysis showed that inner retina was not involved in HCQ toxicity to any meaningful degree, either between stages of retinopathy or after the drug is stopped. The characteristic bull's eye pattern of outer macula thinning appears when comparing moderate retinopathy (before any RPE damage) to the early stage. Later damage, as toxicity evolved to a severe stage, was diffuse across most of the macula. If the drug was stopped at an early or moderate stage, progression was limited to the first year and occurred diffusely without parafoveal localization.RESULTSThe segmentation of retinal layers was verified in SD-OCT cross-sections for all eyes and scans included in this study (a total of 102 scans). Topographic analysis showed that inner retina was not involved in HCQ toxicity to any meaningful degree, either between stages of retinopathy or after the drug is stopped. The characteristic bull's eye pattern of outer macula thinning appears when comparing moderate retinopathy (before any RPE damage) to the early stage. Later damage, as toxicity evolved to a severe stage, was diffuse across most of the macula. If the drug was stopped at an early or moderate stage, progression was limited to the first year and occurred diffusely without parafoveal localization.Hydroxychloroquine retinopathy primarily involves outer retina (photoreceptors). Outer retinal thinning while using HCQ initially involves the parafovea, but becomes diffuse across the macula as damage progresses or after drug cessation. When HCQ is stopped at an early or moderate stage (before RPE damage), progression seems to be limited to the first year.CONCLUSIONSHydroxychloroquine retinopathy primarily involves outer retina (photoreceptors). Outer retinal thinning while using HCQ initially involves the parafovea, but becomes diffuse across the macula as damage progresses or after drug cessation. When HCQ is stopped at an early or moderate stage (before RPE damage), progression seems to be limited to the first year. This report examines the involvement of inner and outer retina in hydroxychloroquine (HCQ) retinopathy, using automated pixel-by-pixel segmentation to measure thickness and rate of change in SD-OCT images. It extends understanding of how toxicity develops and progresses on and off the drug, and shows that HCQ retinopathy involves primarily the outer retina. |
Author | de Sisternes, Luis Rubin, Daniel L. Marmor, Michael F. Hu, Julia |
Author_xml | – sequence: 1 givenname: Luis surname: de Sisternes fullname: de Sisternes, Luis organization: Department of Radiology Stanford University, Stanford, California, United States – sequence: 2 givenname: Julia surname: Hu fullname: Hu, Julia organization: Department of Ophthalmology, Byers Eye Institute at Stanford, Stanford University School of Medicine, Palo Alto, California, United States – sequence: 3 givenname: Daniel L. surname: Rubin fullname: Rubin, Daniel L. organization: Department of Radiology Stanford University, Stanford, California, United States 3Department of Medicine (Biomedical Informatics), Stanford University, Stanford, California, United States – sequence: 4 givenname: Michael F. surname: Marmor fullname: Marmor, Michael F. organization: Department of Ophthalmology, Byers Eye Institute at Stanford, Stanford University School of Medicine, Palo Alto, California, United States |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26024126$$D View this record in MEDLINE/PubMed |
BookMark | eNptkctuEzEUhi1URC-wZIu8ZNEpvs5kWCBVLaWVIiWqgK3l8RxnjCZ2sD1Rw4P0eTtJG1RQV76c_2L5O0YHPnhA6D0lZ5SW1ScX1umMioKWXMhX6IhKyQpZTfjBs_0hOk7pFyGMUkbeoENWEiYoK4_Q_TQY3bs_OrvgcbD4Ui_1ArDzeB7DIkJKbg34etPGcLcxXR9i-D04D_gWsvNhpXO3wTOPtW_xzFqcO8CXcVh8xjfeQ8Q_IaYh4dmQx8POo0_xXEdtwxr0fjyH6FYdRN3jq-39W_Ta6j7Bu6f1BP24-vr94rqYzr7dXJxPCyMkzwW3DbNVCY1oeUvqloMsNeHSTmoj6qa2nMmm0WLCeVUJUlWkpbKUDalLY4kW_AR9ecxdDc0SWgM-j29Qq-iWOm5U0E79O_GuU4uwVkJIySkbAz4-BWz_BVJWS5cM9L32EIakaDkRggtR16P0w_OuvyV7GKOAPwpMDClFsMq4vAMzVrteUaK2yNUWuaJC7ZCPruI_1z74Zf0DyOOxnA |
CitedBy_id | crossref_primary_10_1007_s00347_019_00994_6 crossref_primary_10_1177_08853282211030150 crossref_primary_10_1177_0961203320979038 crossref_primary_10_1016_j_ophtha_2020_10_029 crossref_primary_10_1364_BOE_7_000581 crossref_primary_10_3390_diagnostics14161803 crossref_primary_10_1007_s00417_018_4117_3 crossref_primary_10_1371_journal_pone_0149138 crossref_primary_10_1097_IAE_0000000000002407 crossref_primary_10_1186_s12886_021_01977_5 crossref_primary_10_1016_j_ajo_2018_11_003 crossref_primary_10_1038_s41598_022_15217_3 crossref_primary_10_1080_1744666X_2023_2294938 crossref_primary_10_1097_IAE_0000000000002408 crossref_primary_10_1097_ICB_0000000000000421 crossref_primary_10_1016_j_lfs_2020_117963 crossref_primary_10_1038_s41433_020_01287_y crossref_primary_10_1007_s00296_021_04831_5 crossref_primary_10_1016_j_ophtha_2022_05_002 crossref_primary_10_3389_fphar_2023_1196783 crossref_primary_10_1016_j_jfo_2017_08_002 crossref_primary_10_1007_s11655_024_3922_2 crossref_primary_10_1080_14656566_2024_2412252 crossref_primary_10_1136_bjophthalmol_2018_312363 crossref_primary_10_1007_s12035_022_02825_3 crossref_primary_10_1097_ICB_0000000000001388 crossref_primary_10_1007_s10792_020_01549_4 crossref_primary_10_1016_j_pdpdt_2022_102741 crossref_primary_10_3389_fmed_2022_1026934 crossref_primary_10_1097_ICB_0000000000001108 crossref_primary_10_1016_j_rcreu_2021_05_010 crossref_primary_10_3928_23258160_20160229_02 crossref_primary_10_1111_vop_12890 crossref_primary_10_1016_j_ophtha_2020_06_021 crossref_primary_10_1016_j_ophtha_2015_09_011 crossref_primary_10_15252_emmm_202012476 crossref_primary_10_1186_s12886_024_03684_3 crossref_primary_10_3390_biomedicines8030054 crossref_primary_10_1109_ACCESS_2018_2825397 crossref_primary_10_4103_IJO_IJO_740_23 crossref_primary_10_3390_jpm14050448 crossref_primary_10_1080_15569527_2024_2438629 crossref_primary_10_1097_IAE_0000000000001217 crossref_primary_10_1097_IAE_0000000000003638 crossref_primary_10_1038_eye_2016_298 crossref_primary_10_1016_j_prostaglandins_2020_106522 crossref_primary_10_3390_diagnostics13101752 crossref_primary_10_3390_jpm12091445 crossref_primary_10_1111_ceo_14090 crossref_primary_10_1167_iovs_64_12_29 crossref_primary_10_1364_BOE_9_002955 crossref_primary_10_1016_j_preteyeres_2021_100951 crossref_primary_10_1167_iovs_18_26079 crossref_primary_10_1080_02713683_2018_1545912 crossref_primary_10_1364_BOE_8_001926 crossref_primary_10_1177_0961203319829826 crossref_primary_10_1016_j_ajo_2022_07_028 crossref_primary_10_1097_IAE_0000000000001151 crossref_primary_10_1016_j_jcjo_2019_05_013 crossref_primary_10_1097_IAE_0000000000002047 crossref_primary_10_1097_IAE_0000000000001036 crossref_primary_10_1002_art_41934 crossref_primary_10_1016_j_ajoc_2018_01_019 crossref_primary_10_1167_tvst_12_3_5 crossref_primary_10_1097_IAE_0000000000002437 crossref_primary_10_18231_j_ijceo_2021_092 crossref_primary_10_1016_j_ajo_2017_08_022 crossref_primary_10_1097_ICB_0000000000000750 crossref_primary_10_1097_ICB_0000000000000993 crossref_primary_10_1167_tvst_12_7_8 crossref_primary_10_1016_j_ophtha_2016_04_042 crossref_primary_10_1016_j_oret_2019_04_025 crossref_primary_10_21561_jor_2024_9_1_62 crossref_primary_10_1097_MD_0000000000025688 crossref_primary_10_1016_j_ophtha_2016_01_058 crossref_primary_10_1016_j_media_2020_101893 crossref_primary_10_1159_000495308 crossref_primary_10_1167_tvst_9_9_42 |
ContentType | Journal Article |
Copyright | Copyright 2015 The Association for Research in Vision and Ophthalmology, Inc. 2015 |
Copyright_xml | – notice: Copyright 2015 The Association for Research in Vision and Ophthalmology, Inc. 2015 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.1167/iovs.14-16345 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Retinal Layers in Progressive HCQ Retinopathy |
EISSN | 1552-5783 |
EndPage | 3426 |
ExternalDocumentID | PMC4455312 26024126 10_1167_iovs_14_16345 |
Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NCATS NIH HHS grantid: UL1 TR001085 |
GroupedDBID | --- 18M 2WC 34G 39C 5GY 5RE AAYXX ACGFO ACNCT ADBBV AENEX AFOSN ALMA_UNASSIGNED_HOLDINGS BAWUL CITATION CS3 DIK DU5 E3Z EBS EJD F5P GROUPED_DOAJ GX1 N9A OK1 P2P RPM SJN TR2 TRV W8F WH7 WOQ WOW .55 .GJ 53G AFFNX AI. CGR CUY CVF ECM EIF NPM VH1 X7M ZGI ZXP 7X8 5PM |
ID | FETCH-LOGICAL-c453t-3fb2f76eb4d3d09d3e56a035f89c49b9f325bba48337740770d1565b096cf0a43 |
ISSN | 1552-5783 0146-0404 |
IngestDate | Thu Aug 21 13:56:57 EDT 2025 Thu Jul 10 23:36:51 EDT 2025 Thu Apr 03 07:09:57 EDT 2025 Thu Apr 24 23:13:13 EDT 2025 Tue Jul 01 02:30:09 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c453t-3fb2f76eb4d3d09d3e56a035f89c49b9f325bba48337740770d1565b096cf0a43 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://iovs.arvojournals.org/arvo/content_public/journal/iovs/933929/i1552-5783-56-5-3415.pdf |
PMID | 26024126 |
PQID | 1684434499 |
PQPubID | 23479 |
PageCount | 12 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4455312 proquest_miscellaneous_1684434499 pubmed_primary_26024126 crossref_citationtrail_10_1167_iovs_14_16345 crossref_primary_10_1167_iovs_14_16345 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2015-05-01 |
PublicationDateYYYYMMDD | 2015-05-01 |
PublicationDate_xml | – month: 05 year: 2015 text: 2015-05-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Investigative ophthalmology & visual science |
PublicationTitleAlternate | Invest Ophthalmol Vis Sci |
PublicationYear | 2015 |
Publisher | The Association for Research in Vision and Ophthalmology |
Publisher_xml | – name: The Association for Research in Vision and Ophthalmology |
References | 21071737 - Invest Ophthalmol Vis Sci. 2011 Mar;52(3):1486-92 23661097 - Graefes Arch Clin Exp Ophthalmol. 2013 Oct;251(10):2311-7 23685488 - Indian J Ophthalmol. 2013 Apr;61(4):168-71 25301882 - Invest Ophthalmol Vis Sci. 2014 Nov;55(11):7093-103 25182842 - Ophthalmology. 2015 Jan;122(1):110-6 25425304 - Invest Ophthalmol Vis Sci. 2015 Jan;56(1):396-402 19373270 - Eye (Lond). 2010 Feb;24(2):340-6 102610 - Invest Ophthalmol Vis Sci. 1978 Dec;17(12):1158-75 21292109 - Ophthalmology. 2011 Feb;118(2):415-22 25275721 - JAMA Ophthalmol. 2014 Dec;132(12):1453-60 20395978 - Eye (Lond). 2010 May;24(5):756-62; quiz 763 22159170 - Arch Ophthalmol. 2012 Apr;130(4):461-9 24922444 - JAMA Ophthalmol. 2014 Sep;132(9):1105-12 22365056 - Ophthalmology. 2012 Jun;119(6):1151-8 |
References_xml | – reference: 23685488 - Indian J Ophthalmol. 2013 Apr;61(4):168-71 – reference: 23661097 - Graefes Arch Clin Exp Ophthalmol. 2013 Oct;251(10):2311-7 – reference: 21292109 - Ophthalmology. 2011 Feb;118(2):415-22 – reference: 25301882 - Invest Ophthalmol Vis Sci. 2014 Nov;55(11):7093-103 – reference: 22159170 - Arch Ophthalmol. 2012 Apr;130(4):461-9 – reference: 22365056 - Ophthalmology. 2012 Jun;119(6):1151-8 – reference: 25182842 - Ophthalmology. 2015 Jan;122(1):110-6 – reference: 20395978 - Eye (Lond). 2010 May;24(5):756-62; quiz 763 – reference: 25425304 - Invest Ophthalmol Vis Sci. 2015 Jan;56(1):396-402 – reference: 25275721 - JAMA Ophthalmol. 2014 Dec;132(12):1453-60 – reference: 24922444 - JAMA Ophthalmol. 2014 Sep;132(9):1105-12 – reference: 21071737 - Invest Ophthalmol Vis Sci. 2011 Mar;52(3):1486-92 – reference: 19373270 - Eye (Lond). 2010 Feb;24(2):340-6 – reference: 102610 - Invest Ophthalmol Vis Sci. 1978 Dec;17(12):1158-75 |
SSID | ssj0021120 |
Score | 2.469582 |
Snippet | To evaluate the relative involvement of inner and outer retina in hydroxychloroquine (HCQ) retinopathy while on the drug, and after drug cessation, using data... This report examines the involvement of inner and outer retina in hydroxychloroquine (HCQ) retinopathy, using automated pixel-by-pixel segmentation to measure... |
SourceID | pubmedcentral proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 3415 |
SubjectTerms | Adult Aged Antimalarials - adverse effects Antirheumatic Agents - adverse effects Female Fovea Centralis - pathology Humans Hydroxychloroquine - adverse effects Male Middle Aged Retina Retinal Diseases - chemically induced Retinal Diseases - pathology Tomography, Optical Coherence |
Title | Localization of Damage in Progressive Hydroxychloroquine Retinopathy On and Off the Drug: Inner Versus Outer Retina, Parafovea Versus Peripheral Fovea |
URI | https://www.ncbi.nlm.nih.gov/pubmed/26024126 https://www.proquest.com/docview/1684434499 https://pubmed.ncbi.nlm.nih.gov/PMC4455312 |
Volume | 56 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bjtMwELXKIiFeEHfKTUZCvGRTkthxGt4QpepCl6JlV9q3yk4cNVKbrNqm0vIh_A6_xkycpOlukRZeqiqx07Rz6pnjzJwh5K1WiQ5E7Nuxo3wby2btkCfCDhOXBTwCXGsscD7-JkZn_Mu5f97p_G5lLRVr1Yt-7q0r-R-rwjGwK1bJ_oNlm4vCAXgP9oVXsDC83sjGY3REVSElRn0DucAUnDTD_P-SSGNe0OgyxlyVaAbUHNwAhpUnWOicYzfiS2ti0pEniUkWGCyLsgL6CHtyWbidVqysCTZ-MLOkiTuXMsk3WtYDvsPXLQUK5tYQj7dj3paUB9xNfjFbz-R8YbSfEHibdFXUpZlbnMXa-pGWKg5mIRsX6WqLwbq0u3EqJ4UyagimZt4a97Z77cuF2ZOoSgSsYa-91-H628zCenn2gToHpvVNvX4bYfIKp35rMQYH7e_3EgKfU6f5ZgWOwoaI1Cha7qpxX_GSTe5iyZpEMMXpQJym5fRb5LYHPAVbaAyOvjaM3zW6oM1t1yKvIni_8-m7QdE1pnM1YbcVAZ3eJ_cq6kI_Ghw-IB2dPSR3jqvkjEfkVxuONE-ogSNNM9qCI70OR9qCI51kFOBIAY4U4EgRjh9oCUZqsEZLMJo58pA2UKxPb6FISyg-JmfDz6efRnbV9sOOuM_WNkuUlwRCKx6z2Aljpn0hHeYn_TDioQoT5vlKSd5nDLiLEwRO7AItUUDGo8SRnD0hB1me6WeEKi9Qui-B1cB4z4v6DlMQwfJYxK7nxbJLDuvffRpVmvjYmmU-3WvlLnnXDL8wYjB_G_imNuIUlmt8BicznRcwQvQ5Z5yHYZc8NUZtLuUJCJhdT3RJsGPuZgBKwe-eydJZKQnPYZVlrvf8pjf4gtzd_r9ekoP1stCvILpeq9clgv8AOzLYsQ |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Localization+of+Damage+in+Progressive+Hydroxychloroquine+Retinopathy+On+and+Off+the+Drug%3A+Inner+Versus+Outer+Retina%2C+Parafovea+Versus+Peripheral+Fovea&rft.jtitle=Investigative+ophthalmology+%26+visual+science&rft.au=de+Sisternes%2C+Luis&rft.au=Hu%2C+Julia&rft.au=Rubin%2C+Daniel+L.&rft.au=Marmor%2C+Michael+F.&rft.date=2015-05-01&rft.issn=1552-5783&rft.volume=56&rft.issue=5&rft.spage=3415&rft_id=info:doi/10.1167%2Fiovs.14-16345&rft.externalDBID=n%2Fa&rft.externalDocID=10_1167_iovs_14_16345 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1552-5783&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1552-5783&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1552-5783&client=summon |